3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine → 4-(4-Chloro-phenyl)-6-cyclopropyl-2-(4-pyridin-3-yl-imidazol-1-yl)-pyrimidine

HRID 1928039

反応式

HRID 1928039 の反応式
Br[C:2]1[N:3]=[CH:4][N:5]([C:7]2[N:12]=[C:11]([C:13]3[CH:18]=[CH:17][C:16]([Cl:19])=[CH:15][CH:14]=3)[CH:10]=[C:9]([CH:20]3[CH2:22][CH2:21]3)[N:8]=2)[CH:6]=1.CC1(C)C(C)(C)OB([C:31]2[CH:32]=[N:33][CH:34]=[CH:35][CH:36]=2)O1>>[Cl:19][C:16]1[CH:17]=[CH:18][C:13]([C:11]2[CH:10]=[C:9]([CH:20]3[CH2:22][CH2:21]3)[N:8]=[C:7]([N:5]3[CH:6]=[C:2]([C:31]4[CH:32]=[N:33][CH:34]=[CH:35][CH:36]=4)[N:3]=[CH:4]3)[N:12]=2)=[CH:14][CH:15]=1

参加物

3

反応物 2

HCID 27346563-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridineHCID 574687382-(4-Bromo-imidazol-1-yl)-4-(4-chloro-phenyl)-6-cyclopropyl-pyrimidine

生成物 1

HCID 574688644-(4-Chloro-phenyl)-6-cyclopropyl-2-(4-pyridin-3-yl-imidazol-1-yl)-pyrimidine

実験手順

The title compound was prepared from 2-(4-bromo-imidazol-1-yl)-4-(4-chloro-phenyl)-6-cyclopropyl-pyrimidine (example E.14) (0.15 g, 0.4 mmol) and commercially available 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.08 g, 0.4 mmol) according to the general procedure VI. Obtained as an off-white solid (0.015 g, 10%). MS (ISP) 374.0 [(M+H)+]; mp 180-182° C.

出典と根拠

ORDレコード
ord-3eacac7735f649af9f5944c8c7137c9a
出典データセット
uspto-grants-2012_05
特許番号
US08183262B2

関連ノート

読み込み中…